blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3459551

EP3459551 - USE OF ARSENIC TRIOXIDE IN THE PREVENTION OR TREATMENT OF DISEASES ASSOCIATED WITH TYPE I INTERFERON SYSTEM ACTIVATION [Right-click to bookmark this link]
StatusThe application has been refused
Status updated on  30.08.2019
Database last updated on 06.07.2024
FormerThe application has been published
Status updated on  22.02.2019
Most recent event   Tooltip30.08.2019Refusal of applicationpublished on 02.10.2019  [2019/40]
Applicant(s)For all designated states
Medsenic
11, rue de l'Académie
67000 Strasbourg / FR
[2019/13]
Representative(s)Santarelli
Tour Trinity
1 bis Esplanade de la Défense
92035 Paris La Défense Cedex / FR
[N/P]
Former [2019/13]Santarelli
49, avenue des Champs-Elysées
75008 Paris / FR
Application number, filing date17306250.622.09.2017
[2019/13]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3459551
Date:27.03.2019
Language:EN
[2019/13]
Search report(s)(Supplementary) European search report - dispatched on:EP05.03.2018
ClassificationIPC:A61K33/36, A61P19/04, A61P17/06, A61P5/14, A61P19/02, A61P43/00, A61P3/10
[2019/13]
CPC:
A61K33/36 (EP); A61P17/06 (EP); A61P19/02 (EP);
A61P19/04 (EP); A61P3/10 (EP); A61P43/00 (EP);
A61P5/14 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/13]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:VERWENDUNG VON ARSENTRIOXID ZUR VORBEUGUNG ODER BEHANDLUNG VON ERKRANKUNGEN IM ZUSAMMENHANG MIT TYP I INTERFERON-SYSTEMAKTIVIERUNG[2019/13]
English:USE OF ARSENIC TRIOXIDE IN THE PREVENTION OR TREATMENT OF DISEASES ASSOCIATED WITH TYPE I INTERFERON SYSTEM ACTIVATION[2019/13]
French:UTILISATION DE TRIOXYDE D'ARSENIC DANS LA PRÉVENTION OU LE TRAITEMENT DE MALADIES ASSOCIÉES À L'ACTIVATION DU SYSTÈME D'INTERFÉRON DE TYPE I[2019/13]
Examination procedure29.04.2019Despatch of communication that the application is refused, reason: Examination on filing A.90(5) [2019/40]
12.05.2019Application refused, date of legal effect [2019/40]
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XI]US8394422  (CHELBI ALIX KMAR [FR], et al) [X] 1-5,7,8 * the whole document * * column 1, line 23 - line 44 * * column 1, line 63 - line 67 * * column 2, line 5 - line 24 * * page 2, line 58 - page 3, line 12 * * column 3, line 53 - column 4, line 23 * * examples parts I-II * [I] 6;
 [XI]WO2007028154  (UNIV NORTHWESTERN [US], et al) [X] 1-5,7,8 * the whole document * * page 18, line 23 - line 25 * * page 27, line 4 - page 28, line 5 * * claim 2 * [I] 6;
 [XI]EP1736161  (HSIN SHAO-CHI [TW]) [X] 1-5,7,8 * the whole document * * examples 1-4 * * paragraph [0045] * * claims 1-5 * [I] 6;
 [XI]CN106038594
 [I]  - NILOUFAR KAVIAN ET AL, "Reactive oxygen species-mediated killing of activated fibroblasts by arsenic trioxide ameliorates fibrosis in a murine model of systemic sclerosis", ARTHRITIS & RHEUMATISM, US, (20121001), vol. 64, no. 10, doi:10.1002/art.34534, ISSN 0004-3591, pages 3430 - 3440, XP055452561 [I] 1-8 * the whole document * * abstract * * page 3438, column r, paragraph 2 - page 3439, column r, paragraph l *

DOI:   http://dx.doi.org/10.1002/art.34534
 [I]  - N. KAVIAN ET AL, "Arsenic Trioxide Prevents Murine Sclerodermatous Graft-versus-Host Disease", THE JOURNAL OF IMMUNOLOGY, US, (20120409), vol. 188, no. 10, doi:10.4049/jimmunol.1103538, ISSN 0022-1767, pages 5142 - 5149, XP055452559 [I] 1-8 * the whole document * * abstract * * page 5143, column l, line 1 - line 3 * * page 5146, column l, paragraph 1 - page 5149, column l, paragraph l * * page 5149, column l, line 21 - line 25 *

DOI:   http://dx.doi.org/10.4049/jimmunol.1103538
 [XI]  - DATABASE WPI, 0, Derwent World Patents Index, vol. 2017, no. 01, Database accession no. 2016-683984, XP002778331 & CN106038594 A 20161026 (ZHANG C) [X] 1-5,7,8 * abstract * [I] 6
by applicant   - RONNBLOM et al., Clin. Exp. Rheumatol., (20160000), vol. 34, no. 98, pages S1 - S24
    - DOMIZIO et al., Expert. Rev. Clin. Immunol., (20130000), vol. 9, no. 3
    - CROW et al., J. Immunol., (20140000), vol. 192, no. 12, pages 5459 - 5468
    - TSOKOS et al., New Engl. J. med., (19790000), vol. 365, no. 22, pages 2110 - 2121
    - YTTERBERG et al., Arthritis Rheum., (19820000), vol. 25, no. 4, pages 401 - 6
    - HOOKS et al., "N. Engl.", J. Med., (19790000), vol. 301, no. 1, pages 5 - 8
    - POSTAL et al., Clinics, (20120000), vol. 67, no. 2, pages 157 - 162
    - BENNETT et al., J. Exp. Med., (20030000), vol. 197, pages 711 - 723
    - BAECHLER et al., Proc. Natl. Acad. Sci. USA, (20030000), vol. 100, pages 2610 - 2615
    - CROW et al., Arthritis Res. Ther., (20030000), vol. 5, pages 279 - 287
    - HAN et al., Genes Immun., (20030000), vol. 4, pages 177 - 186
    - BAVE et al., J. Immunol., (20030000), vol. 171, no. 6, pages 3296 - 302
    - BLANCO et al., Science, (20010000), vol. 294, page 15401543
    - IOANNOU et al., Arthritis Rheum., (20000000), vol. 43, no. 7, pages 1431 - 42
    - SIGURDSSON et al., Am. J. Hum. Genet., (20050000), vol. 76, no. 3, pages 528 - 537
    - GILLIET et al., Nat. Rev. Immunol., (20080000), vol. 8, no. 8, pages 594 - 606
    - GOTTENBERG et al., Proc. Natl. Acad. Sci. USA, (20060000), vol. 103, no. 8, pages 2270 - 2275
    - HJELMERVIK et al., Arthritis Rheum., (20050000), vol. 52, pages 1534 - 1544
    - BAECHLER et al., Immunol. Rev., (20060000), vol. 210, pages 120 - 137
    - ELORANTA, Ann. Rheum. Dis., (20100000), vol. 69, no. 7, pages 1396 - 1402
    - BAECHLER et al., Arthrit. Res. Ther., (20110000), vol. 13, no. 6, page 249
    - VAN DER POUW KRAAN et al., Ann. Rheum. Dis., (20070000), vol. 66, pages 1008 - 1014
    - GARDNER et al., Virology, (20120000), vol. 425, pages 103 - 112
    - HIGGS et al., Ann. Rheum. Dis., (20120000), vol. 70, no. 11, pages 2029 - 2036
    - YAO et al., Arthritis Rheum., (20090000), vol. 60, pages 1785 - 1796
    - FURIE et al., Arthritis Rheum., (20150000), vol. 67, page 10
    - PELLERIN et al., EMBO Mol. Med., (20150000), vol. 7, pages 464 - 476
    - ICHIKAWA et al., Arthritis Rheum., (20120000), vol. 64, pages 493 - 503
    - BOBE et al., Blood, (20060000), vol. 108, no. 13, pages 3967 - 3975
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.